SERMs for the treatment and prevention of breast cancer

Reviews in Endocrine and Metabolic Disorders

Volumn 8, Issue 3, 2007, Pages 229-239

  Swaby, Ramona F ^a   Sharma, Catherine G N ^a   Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Endometrial cancer; Estrogen receptor; Osteoporosis; Raloxifene; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; AROMATASE INHIBITOR; ARZOXIFENE; BASEDOXIFENE; FLUOXYMESTERONE; LASOFOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

BLOOD CLOT; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR RISK; CATARACT; CATARACT EXTRACTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIUM CANCER; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; POSTMENOPAUSE; REVIEW; SECONDARY OSTEOPOROSIS; THROMBOEMBOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; POSTMENOPAUSE; PREMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 34948854285     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-007-9034-4     Document Type: Review

References (75)

1. Schinzinger A. Ueber carcinoma mammae [abstract] 18th Congress of the German Society for Surgery. Beilage zum Centralblatt fur Chirurgie 1889;16:55-6.
2. Schinzinger A. Ueber carcinoma mammae [abstract].18th Kongress, Berlin, April 24-27, 1889. Berlin (Germany): Hirschwald. Verhandlungen der Deutschen Gesellschaft fur Chirurgie 1889;28.
3. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7.
4. Beatson CT. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:162-5.
5. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Progr Hormone Res 1962;18:387-414.
6. Jordan VC, Brodie AMH. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007;72:7-25.
7. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery 2003;2:205-13.
8. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984;36:245-76.
9. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001;61:5683-7.
10. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;354:1451-67.
11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
12. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
13. Jordan VC. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Invest 1988;6:589-95.
14. Lerner LJ, Jordan VC. The development of antiestrogens for the treatment of breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990;50:4177-89.
15. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy. JAMA 2004;291:47-53.
16. Riggs BL, Hartmann LC. Selective Estrogen-Receptor Modulators-Mechanisms of Action and Application to Clinical Practice. N Engl J Med 2003;348:618-29.
17. Writing Group for the Women's Health Initiative Investigators, Rossouw JEAG, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-32.
18. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
19. Faber A, Bouvy ML, Loskamp L, van de Berg PB, Egberts ACG, de Jong-van den Berg LTW. Dramatic change in prescribing of hormonal replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005;60:641-7.
20. Ravdin PM, Cronin KA, Howlander N, Chlebowski RT, Berry DA. A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res and Treatment Breast Cancer Research & Treatment 100 Supplement 1,S6:59, 2003.
21. Jordan VC. The science of selective estrogen receptor modulators: concept to clinical practice. Clin Cancer Res 2006;12:5010-3.
22. Jordan VC. SERMs: meeting the promise of multifunctional medicines. (Commentary). J Natl Cancer Inst 2007;99:350-6.
23. Harper MJ, Walpole AL. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967;13:101-19.
24. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. an early clinical appraisal of ICI 46474. Br J Cancer 1971;25:270-5.
25. Jordan VC, Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 1975;11:205-6.
26. Nicholson RI, Golder MP. The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer 1975;11:571-9.
27. Jordan VC, Jaspan T. Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol 1976;68:453-60.
28. Skidmore J, Walpole AL, Woodburn J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J Endocrinol 1972;52:289-98.
29. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977;75:305-16.
30. Langan-Fahey SM, Tormey DC, Jordan VC. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 1990;26:883-8.
31. Jordan VC, Dix CJ, Allen KE. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuv Ther Cancer 1979;2:19-26.
32. Jordan VC, Allen KE. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980;16:239-51.
33. Jordan VC, Allen KE, Dix CJ. Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 1980;64:745-59.
34. EBCTCG. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92.
35. EBCTCG. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
36. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
37. Jordan VC. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 1974;5:354.
38. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 1976;12:419-24.
39. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer [letter]. Lancet 1985;2:282.
40. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
41. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
42. IBIS Investigators. First results from the International Breast Study: a randomized prevention trial. Lancet 2002;360:817-24.
43. Jordan VC. Optimising endocrine approaches for the chemoprevention of breast cancer. Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. Eur J Cancer 2006;42:2909-13.
44. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
45. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
46. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151-9.
47. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. JNCI 2005;97:30-9.
48. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
49. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21.
50. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412-3.
51. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987;10:31-5.
52. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987;2:449-56.
53. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 1988;122:1146-50.
54. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
55. Jordan VC, Robinson SP. Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 1987;46:1870-4.
56. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-5.
57. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
58. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [see comments]. J Natl Cancer Inst 1994;86:527-37.
59. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
60. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. For the CORE investigators continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61.
61. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
62. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [see comments] [published erratum appears in JAMA 1999 Dec 8;282(22):2124]. JAMA 1999;282:637-45.
63. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
64. Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 1990;50:3189-92.
65. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. JAMA 2006;295:2727-41.
66. Jordan VC. Chemoprevention of breast cancer with selective estrogen-receptor modulators. Nat Rev, Cancer 2007;7:46-53.
67. Jordan VC. Beyond raloxifene for the prevention of osteoporosis and breast cancer. Br J Pharmacol. 2007;150:3-4.
68. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 2003;46:1081-111.
69. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-68.
70. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-58.
71. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 2003;289:2651-62.
72. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84.
73. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39:668-77.
74. Miller CP, Collini MD, Tran BD, Harris HA, Kharode YP, Marzolf JT, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44:1654-7.
75. Rosati RL, Da Silva Jardine P, Cameron KO, Thompson DD, Ke HZ, Toler SM, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998;41:2928-31.